MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$19,912,519
Unit: Dollar
Positive Cash Flow Breakdown
Stock-based compensation
Accrued expenses and other liabi...
Depreciation and amortization ex...
Negative Cash Flow Breakdown
Repayment of long-term debt
Net loss
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-5,450,273
-3,452,619
-6,461,507
-7,688,341
Stock-based compensation
1,643,001
-987,554
1,090,081
2,580,754
Non-cash interest expense
0
50,368
50,367
50,368
Net amortization of premium on marketable securities
0
0
44,075
266,560
Depreciation and amortization expense
70,706
66,599
65,116
63,683
Write-off of deferred offering costs
0
0
0
0
Prepaid expenses and other current assets
1,017,606
-470,688
-420,494
-50,152
Accounts payable
-3,880
-17,105
145,038
-1,016,107
Accrued expenses and other liabilities
168,630
-1,240,466
-564,859
-795,365
Net cash used in operating activities
-4,589,422
-5,110,089
-5,299,345
-7,021,416
Acquisitions of fixed assets
23,097
-
-
-
Purchases of marketable securities
0
0
0
0
Maturities of marketable securities
0
0
16,000,000
25,000,000
Net cash (used in) provided by investing activities
-23,097
0
16,000,000
25,000,000
Proceeds from issuance of common stock, net of issuance costs
-
-
-
0
Issuance costs
-
-
0
-
Proceeds from exercise of stock options
0
71,140
0
120,746
Proceeds from employee stock purchase plan
0
0
0
0
Repayment of long-term debt
15,000,000
-
-
-
Debt end of term charge paid in cash
300,000
-
0
-
Net cash provided by (used in) financing activities
-15,300,000
71,140
0
120,746
Net decrease in cash and cash equivalents
-19,912,519
-5,038,949
10,700,655
18,099,330
Cash and cash equivalents, beginning of period
65,002,305
70,041,254
59,340,599
54,527,092
Cash and cash equivalents, end of period
45,089,786
65,002,305
70,041,254
59,340,599
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net decrease in cash
and cash...
-$19,912,519
(-49.88%↓ Y/Y)
Stock-based compensation
$1,643,001
(-32.12%↓ Y/Y)
Accrued expenses and
other liabilities
$168,630
(103.39%↑ Y/Y)
Depreciation and
amortization expense
$70,706
(-42.61%↓ Y/Y)
Net cash provided by
(used in) financing...
-$15,300,000
(-1625.71%↓ Y/Y)
Net cash used in
operating activities
-$4,589,422
(78.17%↑ Y/Y)
Net cash (used in)
provided by investing...
-$23,097
(-100.34%↓ Y/Y)
Canceled cashflow
$1,882,337
Repayment of long-term
debt
$15,000,000
Debt end of term
charge paid in cash
$300,000
Net loss
-$5,450,273
(72.33%↑ Y/Y)
Acquisitions of fixed assets
$23,097
Prepaid expenses and
other current assets
$1,017,606
(243.66%↑ Y/Y)
Accounts payable
-$3,880
(-100.46%↓ Y/Y)
Buy us a coffee
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)